Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Neogenomics Inc (NEO)

Neogenomics Inc (NEO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
2 High-Flying Stocks to Consider Right Now and 1 That Underwhelm

2 High-Flying Stocks to Consider Right Now and 1 That Underwhelm

DRS : 45.84 (+2.96%)
NEO : 7.83 (+5.53%)
BWXT : 213.38 (+4.35%)
3 Russell 2000 Stocks We Approach with Caution

3 Russell 2000 Stocks We Approach with Caution

RUSHA : 66.51 (+0.61%)
NEO : 7.83 (+5.53%)
DBRG : 15.44 (+0.13%)
NeoGenomics, Natera, and Amphastar Pharmaceuticals Shares Skyrocket, What You Need To Know

NeoGenomics, Natera, and Amphastar Pharmaceuticals Shares Skyrocket, What You Need To Know

NTRA : 202.23 (+1.12%)
NEO : 7.83 (+5.53%)
AMPH : 20.06 (+2.40%)
NeoGenomics’ PanTracer LBx Receives Medicare Coverage, Expanding Access to Comprehensive Liquid Biopsy Profiling

NeoGenomics, Inc. (NASDAQ: NEO) , a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the PanTracer™ LBx test has received coverage from the Centers...

NEO : 7.83 (+5.53%)
3 Reasons to Avoid NEO and 1 Stock to Buy Instead

3 Reasons to Avoid NEO and 1 Stock to Buy Instead

NEO : 7.83 (+5.53%)
NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor Types

We estimate that MRD represents a $20+ billion addressable market, growing at 30% annually, which we believe is less than 10% penetrated

NEO : 7.83 (+5.53%)
5 Insightful Analyst Questions From NeoGenomics’s Q4 Earnings Call

5 Insightful Analyst Questions From NeoGenomics’s Q4 Earnings Call

NEO : 7.83 (+5.53%)
Why NeoGenomics (NEO) Shares Are Falling Today

Why NeoGenomics (NEO) Shares Are Falling Today

NEO : 7.83 (+5.53%)
NeoGenomics to Participate in Upcoming Investor Conferences

NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the Company will participate in the following investor conferences:...

NEO : 7.83 (+5.53%)
NEO Q4 Deep Dive: Product Mix Shift and Guidance Weigh on Outlook

NEO Q4 Deep Dive: Product Mix Shift and Guidance Weigh on Outlook

NEO : 7.83 (+5.53%)

Barchart Exclusives

With Aluminum Prices in the Spotlight, 1 Analyst Thinks Constellium Stock Can Still Gain 22% from Here
As aluminum prices hit multi-year highs and supply constraints mount, BMO Capital sees Constellium poised for 10% gains ahead. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.